

550, 982

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085361 A1

(51) International Patent Classification⁷: **C07C 43/23**,
C07D 209/32, 333/12

Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). **WARDMAN, Peter** [GB/GB]; The Gray Cancer Institute, P.O. Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB).

(21) International Application Number:
PCT/GB2004/001341

(22) International Filing Date: 26 March 2004 (26.03.2004)

(74) Agent: **SRINIVASAN, Ravi, Chandran**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0306908.5 26 March 2003 (26.03.2003) GB

(71) Applicants (for all designated States except US): **ANGIOGENE PHARMACEUTICALS LIMITED** [GB/GB]; The Magdalen Centre, The Oxford Science Park, Oxfordshire OX4 4GA (GB). **GRAY LABORATORY CANCER RESEARCH TRUST** [GB/GB]; PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAVIS, Peter, David** [GB/GB]; Angiogene Pharmaceuticals Limited, The Magdalen Centre, Oxford Science Park, Oxfordshire OX4 4GA (GB). **NAYLOR, Matthew, Alexander** [GB/GB]; The Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). **THOMSON, Peter** [GB/GB]; The Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). **EVERETT, Steven, Albert** [GB/GB]; The Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). **STRATFORD, Michael, Richard, Lacey** [GB/GB]; The


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: **BIOREDUCTIVELY ACTIVATED STILBENE PRODRUGS**



(I)



(II)



(III)

(57) Abstract: A compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein Ar is a substituted heteroaryl group bearing at least one nitro or azido group or is a group of formula (2) or (3); R₁ is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; R₂ is alkyl, alkoxy, thialkoxy or halo; R₃, R₄ and R₅ are each independently alkyl, alkoxy, thialkoxy or halo with the proviso that at least two of R₃, R₄ or R₅ are alkoxy; L is -OC(O)- or -OP(O)(OR₆)-; n is 0 or 1; X is O, S or NR₇; Y is hydrogen, alkyl, alkoxy, thialkoxy, halo, hydroxy or dihydrogenphosphate; R₆ is hydrogen or alkyl; R₇ is hydrogen or alkyl; R₈ is hydrogen, alkoxy or dialkylaminoalkyl; R₉ is optionally substituted alkyl; R₁₀ is hydrogen, alkyl, alkoxy or dialkylaminoalkyl; R₁₁ and R₁₂ are independently hydrogen, alkyl, alkoxy, thialkoxy, amino, dialkylamino, morpholino, alkylmorpholino, piperidino, alkylpiperidino, piperazino, alkylpiperazino or 1-aziridinyl; and A, together with the carbon atoms to which it is fused, is an optionally substituted aryl or heteroaryl ring.

WO 2004/085361 A1